FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034861381> ?p ?o ?g. }

• W2034861381 endingPage "375" @default.
• W2034861381 startingPage "367" @default.
• W2034861381 abstract "The objective of this study was to compare the efficacy of 3 regimens, cladribine alone, cladribine and cyclophosphamide combination, or cyclophosphamide, vincristine, and prednisone combination in previously untreated patients with low-grade B-cell non-Hodgkin lymphoma (LGNHL).For this 3-arm, phase 3 study, 197 patients were randomly allocated to receive 6 monthly courses of cladribine alone, cladribine and cyclophosphamide combination, or cyclophosphamide, vincristine, and prednisone combination. Patients for whom all clinical data were available and 162 patients who completed scheduled chemotherapy were analyzed for the endpoints of this study.Compared with cyclophosphamide, vincristine, and prednisone combination regimen, cladribine alone or cladribine and cyclophosphamide combination induced higher probability of overall response (odds ratio [OR] = 4.0; 95% confidence interval [CI], 1.7-9,3; P = .002, and OR = 8.5; 95% CI, 3.2-22.7; P < .0001, respectively), complete remission (OR = 5.8; 95% CI, 1.8-18.5; P = .003; and OR = 14; 95% CI, 4.4-44; P < .0001, respectively), progression-free survival (log-rank test P < .0001), but not overall survival. After incorporating the International Prognostic Index in multivariate analysis, treatment with cladribine-containing regimens remained an independent prognostic factor for progression-free survival (chi(2) = 35.94; hazard ratio = 2.38; P < .0002). Incidences of infections were similar in the randomized groups, whereas cladribine and cyclophosphamide combination, but not cladribine alone, induced more frequent neutropenia, anemia, and thrombocytopenia compared with cyclophosphamide, vincristine, and prednisone combination (P < .05 for each). This resulted in a higher frequency of prolongation of intervals between cladribine and cyclophosphamide combination and cyclophosphamide, vincristine, and prednisone combination cycles (P < .05), but dose reductions due to hematological or other toxicity did not differ significantly in cladribine alone, cladribine and cyclophosphamide combination, and cyclophosphamide, vincristine, and prednisone combination groups.For patients with LGNHL, first-line cladribine alone or cladribine and cyclophosphamide combination regimens both provided similar treatment responses, acceptable toxicity, and better response rates than cyclophosphamide, vincristine, and prednisone combination." @default.
• W2034861381 created "2016-06-24" @default.
• W2034861381 creator A5019711205 @default.
• W2034861381 creator A5022628384 @default.
• W2034861381 creator A5032050013 @default.
• W2034861381 creator A5037324699 @default.
• W2034861381 creator A5042016815 @default.
• W2034861381 creator A5046149432 @default.
• W2034861381 creator A5056728544 @default.
• W2034861381 creator A5078900537 @default.
• W2034861381 creator A5083104263 @default.
• W2034861381 creator A5087571749 @default.
• W2034861381 date "2008-07-15" @default.
• W2034861381 modified "2023-10-15" @default.
• W2034861381 title "Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non‐Hodgkin lymphoma patients" @default.
• W2034861381 cites W1507320147 @default.
• W2034861381 cites W1874821077 @default.
• W2034861381 cites W1912693401 @default.
• W2034861381 cites W1921096083 @default.
• W2034861381 cites W1921508210 @default.
• W2034861381 cites W1982790762 @default.
• W2034861381 cites W2095520712 @default.
• W2034861381 cites W2104729833 @default.
• W2034861381 cites W2106072062 @default.
• W2034861381 cites W2109772420 @default.
• W2034861381 cites W2134057518 @default.
• W2034861381 cites W2136326451 @default.
• W2034861381 cites W2150677488 @default.
• W2034861381 cites W2152229600 @default.
• W2034861381 cites W2154643481 @default.
• W2034861381 cites W2157514847 @default.
• W2034861381 cites W2161958805 @default.
• W2034861381 cites W2163790170 @default.
• W2034861381 cites W2169578616 @default.
• W2034861381 cites W2187116010 @default.
• W2034861381 cites W2243293990 @default.
• W2034861381 cites W2266889995 @default.
• W2034861381 cites W2296484683 @default.
• W2034861381 cites W2550328134 @default.
• W2034861381 cites W2608724752 @default.
• W2034861381 cites W2981290419 @default.
• W2034861381 doi "https://doi.org/10.1002/cncr.23558" @default.
• W2034861381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18470902" @default.
• W2034861381 hasPublicationYear "2008" @default.
• W2034861381 type Work @default.
• W2034861381 sameAs 2034861381 @default.
• W2034861381 citedByCount "23" @default.
• W2034861381 countsByYear W20348613812012 @default.
• W2034861381 countsByYear W20348613812013 @default.
• W2034861381 countsByYear W20348613812014 @default.
• W2034861381 countsByYear W20348613812016 @default.
• W2034861381 countsByYear W20348613812017 @default.
• W2034861381 countsByYear W20348613812019 @default.
• W2034861381 countsByYear W20348613812022 @default.
• W2034861381 crossrefType "journal-article" @default.
• W2034861381 hasAuthorship W2034861381A5019711205 @default.
• W2034861381 hasAuthorship W2034861381A5022628384 @default.
• W2034861381 hasAuthorship W2034861381A5032050013 @default.
• W2034861381 hasAuthorship W2034861381A5037324699 @default.
• W2034861381 hasAuthorship W2034861381A5042016815 @default.
• W2034861381 hasAuthorship W2034861381A5046149432 @default.
• W2034861381 hasAuthorship W2034861381A5056728544 @default.
• W2034861381 hasAuthorship W2034861381A5078900537 @default.
• W2034861381 hasAuthorship W2034861381A5083104263 @default.
• W2034861381 hasAuthorship W2034861381A5087571749 @default.
• W2034861381 hasBestOaLocation W20348613811 @default.
• W2034861381 hasConcept C126322002 @default.
• W2034861381 hasConcept C141071460 @default.
• W2034861381 hasConcept C143998085 @default.
• W2034861381 hasConcept C207103383 @default.
• W2034861381 hasConcept C2776694085 @default.
• W2034861381 hasConcept C2776755627 @default.
• W2034861381 hasConcept C2778476033 @default.
• W2034861381 hasConcept C2778720950 @default.
• W2034861381 hasConcept C2779200787 @default.
• W2034861381 hasConcept C2779429289 @default.
• W2034861381 hasConcept C44249647 @default.
• W2034861381 hasConcept C71924100 @default.
• W2034861381 hasConcept C90924648 @default.
• W2034861381 hasConceptScore W2034861381C126322002 @default.
• W2034861381 hasConceptScore W2034861381C141071460 @default.
• W2034861381 hasConceptScore W2034861381C143998085 @default.
• W2034861381 hasConceptScore W2034861381C207103383 @default.
• W2034861381 hasConceptScore W2034861381C2776694085 @default.
• W2034861381 hasConceptScore W2034861381C2776755627 @default.
• W2034861381 hasConceptScore W2034861381C2778476033 @default.
• W2034861381 hasConceptScore W2034861381C2778720950 @default.
• W2034861381 hasConceptScore W2034861381C2779200787 @default.
• W2034861381 hasConceptScore W2034861381C2779429289 @default.
• W2034861381 hasConceptScore W2034861381C44249647 @default.
• W2034861381 hasConceptScore W2034861381C71924100 @default.
• W2034861381 hasConceptScore W2034861381C90924648 @default.
• W2034861381 hasIssue "2" @default.
• W2034861381 hasLocation W20348613811 @default.
• W2034861381 hasLocation W20348613812 @default.
• W2034861381 hasOpenAccess W2034861381 @default.
• W2034861381 hasPrimaryLocation W20348613811 @default.
• W2034861381 hasRelatedWork W1978407841 @default.

• next